BioRestorative Therapies, Inc. - Common Stock (BRTX)
1.0980
-0.0120 (-1.08%)
NASDAQ · Last Trade: Nov 22nd, 2:12 AM EST
Detailed Quote
Previous Close
1.110
Open
1.100
Bid
1.020
Ask
1.110
Day's Range
1.040 - 1.110
52 Week Range
1.040 - 2.550
Volume
60,097
Market Cap
9.75M
PE Ratio (TTM)
-0.7469
EPS (TTM)
-1.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
304,199
Chart
About BioRestorative Therapies, Inc. - Common Stock (BRTX)
Biorestorative Therapies Inc is a biotechnology company focused on developing innovative solutions for regenerative medicine, particularly in the areas of musculoskeletal and metabolic diseases. The company is engaged in researching and commercializing therapeutic products using advanced cellular technologies, including adult stem cells. Biorestorative Therapies aims to create treatments that enhance the body's natural healing processes, with a commitment to addressing unmet medical needs and improving patient outcomes through its proprietary methods and therapies. Read More
DETROIT, MICHIGAN - July 16, 2025 ( NEWMEDIAWIRE ) - Lance Alstodt, CEO of BioRestorative Therapies (NASDAQ: BRTX), was recently a guest on Benzinga’s All-Access.
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based
DETROIT, MICHIGAN - April 23, 2025 ( NEWMEDIAWIRE ) - Lance Alstodt, CEO of BioRestorative Therapies (NASDAQ: BRTX), was recently a guest on Benzinga’s All-Access.
